Manufacturing Process of CAR-T Therapy and Assessment of the Optimization Potential

Jiayi Wang; Kaixin Wang

doi:10.62051/bmqtq252

Authors

Jiayi Wang
Kaixin Wang

DOI:

https://doi.org/10.62051/bmqtq252

Keywords:

CAR-T; manufacturing process; gene editing.

Abstract

One ground-breaking novel treatment that is being utilized extensively in the field of cancer treatment is chimeric antigen receptor (CAR)-T cell therapy. Three axes are used by CAR-T cells to promote tumor killing: Targeting the antigen-positive fraction is the Perforin and Granzyme axis; Targeting the antigen-negative fraction is the Fas and FasL axis; and Cytokine release is focused on the Stromal cell. As a result of this technology's widespread use, its benefits and applications have increased; yet, drawbacks and toxicities have also been discovered. The wide range of uses for this cutting-edge technology has resulted in an increase in its advantages and uses. Alongside these benefits, studies have also discovered negative effects and toxicities related to its usage. This work analyzes the complexities of the specialized immunotherapy mechanism, the difficulties associated with this technology, toxicity issues, and future directions in the treatment of CAR-T cells. Its potential to completely transform the way cancer is treated is becoming more and more evident as the medical community works to understand the intricacies of this innovative therapy.

Downloads

Download data is not yet available.

References

Kumar, B. V., Connors, T. J., & Farber, D. L. Human T Cell Development, Localization, and Function throughout Life. Immunity, 2018, 48 (2), 202 – 213.

Benmebarek, M. R., Karches, C. H., Cadilha, B. L., Lesch, S., Endres, S., & Kobold, S. Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. International journal of molecular sciences, 2019, 20 (6), 1283.

Sterner, R. C., & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood cancer journal, 2021, 11 (4), 69.

Alabanza, L. et al. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol. Ther. 2017, 25, 2452 – 2465.

Kawalekar, O. U., O’Connor, R. S., Fraietta, J. A., Guo, L., McGettigan, S. E., Posey, A. D., & June, C. H. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity, 2016, 44 (2), 380 - 390.

Maus, M. V., & Levine, B. L. Chimeric antigen receptor T-cell therapy for the community oncologist. The Oncologist, 2016, 21 (5), 608 - 617.

Artis, D., & Spits, H. The biology of innate lymphoid cells. Nature, 2015, 517 (7534), 293 – 301.

Kagi, D., Vignaux, F., Ledermann, B., Biirki, K., & Depraetere, V. S. Nagata. H. Hengartner, and P. Golstein. Fas and perforin pathways as major mechanisms of T-cell mediated cytotoxicity. Science, 1994, 265, 528.

Nagata, S., & Tanaka, M. Programmed cell death and the immune system. Nature Reviews Immunology, 2017, 17 (5), 333 - 340.

Hong, L. K., Chen, Y., Smith, C. C., Montgomery, S. A., Vincent, B. G., Dotti, G., & Savoldo, B. CD30-Redirected chimeric antigen receptor T cells target CD30+ and CD30− embryonal Carcinoma via antigen-Dependent and Fas/FasL interactions. Cancer immunology research, 2018, 6 (10), 1274 - 1287.

Smith, J. D. Advancements in CAR-T Cell Therapy: A Summary. Journal of Immunotherapy, 2023, 10 (4), 250 - 265.

Hong M, Clubb J D, Chen Y Y. Engineering CAR-T cells for next-generation cancer therapy. Cancer cell, 2020, 38 (4): 473 - 488.